CellCentric
Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma
$220MSeries D
Role not disclosedRC
RA Capital Management
Activity from announced rounds
Activity in this selectionUnited Kingdom
RA Capital Management founds, funds and scales companies in healthcare and planetary health, combining scientific research with capital from seed through public-market financings.
Its TechAtlas research platform informs investment decisions through detailed scientific and market analysis. Raven, its healthcare incubator, works on originating and co-creating companies, giving researchers a route from a scientific idea to a funded business.
Blackbird provides a clinical development accelerator alongside the investment platform. These capabilities are relevant for founders who need to design a development programme and reach clinical milestones, as well as finance laboratory or commercial work.
Sources
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $220M 1 disclosed · full round size, not this investor’s share